T Lymphocyte Activation in Myasthenic Thymoma

References

• Fujii Y., Monden Y., Nakahara K., et al. Antibody to acetylcholine receptor in myasthenia gravis: Production by lymphocytes from thymus or thymoma. Neurology 1984; 34: 1182–86
   PubMed Web of Science ®Google Scholar
• Namba T., Brunner N. G., Grob D. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine 1978; 57: 411–33
   PubMed Web of Science ®Google Scholar
• Monden Y., Nakahara K., Kogatani K., et al. Myasthenia gravis with thymoma: analysis of and postoperative prognosis for 65 patients with thymomatous myasthenia gravis. Ann. Thorac. Surg. 1984; 38: 46–52
   PubMed Web of Science ®Google Scholar
• Paletto A., Maggi G. Thymectomy in the treatment of myasthenia gravis: results in 320 patients. Int. Surg. 1982; 67: 13
   PubMedGoogle Scholar
• Evoli A., Batocchi A. P., Provenzano C., et al. Thymectomy in the treatment of myasthenia gravis: report of 247 patients. J. Neurol. 1988; 235: 272
   PubMed Web of Science ®Google Scholar
• Takahashi K., Monden Y., Saito S., et al. Myasthenia gravis induces the activation and maturation of lymphocytes in thymoma. J. Clin. Immunol. 1996; 16: 190–97
   PubMedGoogle Scholar
• Brown G., Greaves M. F., Lister T. A., et al. Expression of human T and B lymphocyte cell-surface markers on leukemic cells. Lancet 1974; 2: 753–55
   PubMedGoogle Scholar
• Levine G. D., Polliack A. The T-cell nature of lymphocytes in two human epithelial thymomas: A comparative immunogenic scanning and transmission electron microscopic study. Clin. Immunol, Immunopathol. 1975; 4: 199–208
   PubMedGoogle Scholar
• Crossman J., Deegan M. A., Schnitzer B. Thymoma: An immunologic and electron microscopic study. Cancer 1978; 41: 2183–91
   PubMed Web of Science ®Google Scholar
• Lauriola L., Maggiano N., Marino M., et al. Human thymoma: Immunologic characteristics of the lymphocytic component. Cancer 1981; 48: 1992–95
   PubMedGoogle Scholar
• Christadoss P., Lindstorm J. M., Talal N., et al. Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor. Specific helper factor derived from lymphocytes of myasthenic mice. J. Immunol. 1986; 137: 1845–49
   PubMed Web of Science ®Google Scholar
• Gordon J., Millsum M. J., Guy G. R., et al. Synergistic interaction between interleukin 4 and anti-Bp50 (CDw40) revealed in novel B cell restimulation assay. Eur. J. Immunol. 1987; 17: 1535–38
   PubMedGoogle Scholar
• Jabara H. H., Fu S. M., Geha R. S., et al. CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J. Exp. Med. 1990; 172: 1861–64
   PubMed Web of Science ®Google Scholar
• Gascon H., Gauchat J. F., Aversa G., et al. Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce lgG4 and IgE switching in purified human B cells via different signaling pathways. J. Immunol. 1991; 147: 8–13
   PubMed Web of Science ®Google Scholar
• Zhang K., Clark E. A., Saxon A. CD40 stimulation provides an IFN independent and IL-4-dependent differentiation signal directly to human B cells for IgE production. J. Immunol. 1991; 146: 1836–42
   PubMed Web of Science ®Google Scholar
• Sahapira S. K., Vercelli E., Jabara H. H., et al. Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J. Exp. Med. 1992; 175: 289–92
   PubMedGoogle Scholar
• Defrance T., Vanbervliet B., Briere B. F., et al. Interleukin 10 and transfection growth factor b cooperate to induce anti-CD40-activated naive human B cell to secrete immunoglobulin A. J. Exp. Med. 1992; 175: 671–82
   PubMed Web of Science ®Google Scholar
• Lozte M. T., Grimm E. A., Maunder A., et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured with T-cell growth factor. Cancer Res. 1981; 41: 4420–25
   PubMedGoogle Scholar
• Toribio M. I., Landazuri M. O., Lopez-Botet M. Induction of natural killer-like cytotoxicity in cultured human thymocytes. Eur. J. Immunol. 1983; 13: 964–69
   PubMedGoogle Scholar
• Perlo V. P., Poskanzer D. C., Schwab R. S., et al. Myasthenia gravis: Evaluation of treatment in 1335 patients. Neurology 1996; 16: 431–39
   Google Scholar
• Berrih S., Morel E., Gaud C., et al. Anti-AChR antibodies, thymic histology, and T cell subsets in Myasthenia Gravis. Neurology 1984; 34: 66–71
   PubMed Web of Science ®Google Scholar
• Kato K., Yamada T., Onda H., et al. Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. Biochem. Biophys. Res. 1985; 31: 692–99
   Google Scholar
• Takahashi K., Sone S., Kimura S., et al. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Chest 1993; 103: 1732–38
   PubMedGoogle Scholar
• Takahashi K., Sone S., Saito S., et al. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion. Jpn. J. Cancer Res. 1995; 86: 861–66
   PubMedGoogle Scholar
• Torten M., Sidell N., Golub S. H. Interleukin 2 and stimulator lymphoblastoid cells will induced human thymocytes to bind and kill K.562 targets. J. Exp. Med. 1982; 156: 1545–50
   PubMedGoogle Scholar
• Lopez-Botet M., Moretta L. Functional characterization of human thymocytes: A limiting dilution analysis of precursors with proliferative and cytolytic activities. J. Immunol. 1985; 134: 2299–304
   PubMedGoogle Scholar
• Blue M., Levine H., Daley J. F., et al. Development of natural killer cells in human thymocytes culture: regulation by accessory cells. Eur. J. Immunol. 1987; 17: 669–73
   PubMed Web of Science ®Google Scholar
• Lanier L. L., Benike C. J., Phillips J. H., et al. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J. Immunol. 1985; 134: 794–801
   PubMed Web of Science ®Google Scholar
• Itoh K., Tilden A. B., Kumagai K., et al. Leu-11 + lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL-2)-induced activated killer (AK) cells. J. Immunol. 1985; 134: 802–7
   PubMed Web of Science ®Google Scholar
• Ferradini L., Miescher S., Stoeck M., et al. Cytotoxic potential despite impaired activation pathway in T lymphocytes infiltrating nasopharyngeal carcinoma. Int. J. Cancer 1991; 47: 362–70
   PubMed Web of Science ®Google Scholar
• Ioannides C. G., Plastsoucas C D, Rashed S., et al. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. 1991; 51: 4257–65
   PubMed Web of Science ®Google Scholar
• Cohen-Kaminsky S., Levasseur P., Binet J. P., et al. Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: possible role in autoimmune pathogenesis. J. Neuroimmunol. 1989; 24: 75–85
   PubMedGoogle Scholar
• Cohen-Kaminsky S., Gaud C., Morel E., et al. High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes from patients with myasthenia gravis: correlations with clinical parameters. J. Autoimmunity 1989; 2: 241–58
   PubMedGoogle Scholar
• Loh R. K., Jabara H. H., Geha R. S. Mechanisms of inhibition of IgE synthesis by nedocromil sodium: nedo-cromil inhibits deletional switch recombination in human B cells. J. Allergy Clin. Immunol. 1996; 97: 1141–50
   PubMedGoogle Scholar